2Institute of Molecular Genetics, Russian Academy of Sciences, pl. Kurchatova 2, Moscow 123182, Russia; fax: (7-095) 196-0221
3Faculty of Biology, Lomonosov Moscow State University, Moscow 117899, Russia; fax: (7-095) 147-3897
4State Research Center for Institute of Highly Pure Biopreparations, Ministry of Health of the Russian Federation, Pudozhskaya ul. 7, St. Petersburg 197110, Russia; fax: (7-812) 235-5504
5Department of Medicine, University of Maryland School of Medicine, 10 S. Pine St., Baltimore, MD 21201, USA; fax: (1-410) 706-0321
* To whom correspondence should be addressed.
Received September 24, 2003; Revision received November 4, 2003
beta-Endorphin-like decapeptide immunorphin (SLTCLVKGFY), a selective agonist of non-opioid beta-endorphin receptor, was labeled with tritium to specific activity of 24 Ci/mmol. It was used for the detection and characterization of non-opioid beta-endorphin receptors on rat adrenal cortex membranes (Kd1 = 39.6 ± 2.0 nM, Bmax1 = 40.7 ± 2.3 pmol/mg protein; Kd2 = 0.25 ± 0.01 µM, Bmax2 = 187.8 ± 9.4 pmol/mg protein). beta-Endorphin was found to inhibit the [3H]immunorphin specific binding to membranes (Ki = 70.0 ± 9.2 nM); naloxone, [Met5]enkephalin, and alpha- and gamma-endorphins tested in parallel were inactive. Immunorphin at concentrations of 10-9-10-6 M was found to inhibit the adenylate cyclase activity in adrenocortical membranes, while intramuscular injection of immunorphin at doses of 10-100 µg/kg was found to reduce the secretion of 11-oxycorticosteroids from the adrenals to the bloodstream.
KEY WORDS: beta-endorphin, naloxone, peptides, receptors, adrenal cortex